Olssa (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olssa, is a angiotensin II receptor blocker presented as a oral tablet for oral use. It treats hypertension, often in combination with a calcium‑channel blocker, and is intended for adult patients. GNH USA supplies Olssa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olssa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olssa combines two antihypertensive agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone.

- Hypertension: improves blood pressure control when monotherapy is insufficient. - Chronic kidney disease with hypertension: slows progression of proteinuria. - Heart failure with reduced ejection fraction: adjunctive therapy to reduce afterload. - Diabetes‑related hypertension: provides renal protective benefits. - High‑risk cardiovascular patients: lowers risk of stroke and myocardial infarction. - Elderly patients with isolated systolic hypertension: offers better tolerability.

Olssa may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after the first dose. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angio‑edema: swelling of face, lips or throat. - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: elevated liver enzymes. - Acute kidney injury: sudden loss of kidney function. - Myocardial infarction: rare but reported. - Hyperkalemia: elevated potassium levels.

When prescribing Olssa, clinicians should consider several safety aspects.

- Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: adjust use in patients with impaired kidneys. - Check electrolytes: especially potassium levels. - Review concomitant antihypertensives: avoid excessive additive effects. - Pregnancy warning: avoid use in pregnancy due to fetal toxicity. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Olssa can interact with several drug classes, requiring careful management.

Major Interactions (Avoid):\n- Potassium‑sparing diuretics: risk of hyper‑kalemia. - ACE inhibitors or other ARBs: additive hypotensive effect. - Strong CYP3A4 inhibitors: increased amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy. - Lithium: altered renal clearance may increase toxicity. - Simvastatin: amlodipine can raise statin concentrations, increasing myopathy risk.